Aquestive Therapeutics (AQST) EBITDA Margin (2017 - 2026)
Aquestive Therapeutics' (AQST) quarterly EBITDA Margin came in at 29.1% in Q1 2026, up 19297.0% year-on-year from N/an in Q1 2025, and down 130.87% quarter-over-quarter from 94.27% in Q4 2025.
Aquestive Therapeutics (AQST) EBITDA Margin (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' EBITDA Margin history runs 10 years deep, the most recent figure standing at 29.1% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 19297.0% year-over-year to 29.1% in Q1 2026; TTM through Mar 2026 was 838.69%, a 76275.0% decrease from a year earlier, with the FY2025 full-year figure at 7574.73%, down 752128.0% from the prior year.
- EBITDA Margin declined to 29.1% in Q1 2026 per AQST's latest filing, from 94.27% in the prior quarter.
- Across five years, EBITDA Margin topped out at 94.27% in Q4 2025 and bottomed at 222.08% in Q1 2025.
- The 5-year median for EBITDA Margin is 74.31% (2024), against an average of 67.49%.
- Biggest YoY gain for EBITDA Margin was 20870 bps in 2025; the steepest drop was 14776 bps in 2025.
- Year by year, EBITDA Margin stood at 100.29% in 2022, then surged by 70 bps to 29.62% in 2023, then sank by 286 bps to 114.43% in 2024, then jumped by 182 bps to 94.27% in 2025, then slumped by 131 bps to 29.1% in 2026.
- Per Business Quant, the three latest AQST EBITDA Margin figures stand at 29.1% (Q1 2026), 94.27% (Q4 2025), and 89.63% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Aquestive Therapeutics | 462.24 Mn | 462.24 Mn | 13.47 Mn | -29.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.10% |
| Dec 31, 2025 | 94.27% |
| Sep 30, 2025 | -89.63% |
| Jun 30, 2025 | -113.65% |
| Mar 31, 2025 | -222.08% |
| Dec 31, 2024 | -114.43% |
| Sep 30, 2024 | -61.22% |
| Jun 30, 2024 | 0.27% |
| Mar 31, 2024 | -74.31% |
| Dec 31, 2023 | -29.62% |
| Sep 30, 2023 | -18.28% |
| Jun 30, 2023 | -31.79% |
| Mar 31, 2023 | -41.36% |
| Dec 31, 2022 | -100.29% |
| Sep 30, 2022 | -77.23% |
| Jun 30, 2022 | -159.53% |
| Mar 31, 2022 | -79.36% |
| Dec 31, 2021 | -105.33% |
| Sep 30, 2021 | -59.97% |
| Jun 30, 2021 | -325.85% |